- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Crystal S. Denlinger Calls for Personalized Care in Cancer Survivorship
As innovations in cancer care transform the disease into a chronic illness, the survivorship population encompasses more than early stage patients but survivors of long term metastatic disease as well, explains Crystal S. Denlinger, MD, Fox Chase Cancer Center in Philadelphia.
As innovations in cancer care transform the disease into a chronic illness, Crystal S. Denlinger, MD, Fox Chase Cancer Center in Philadelphia, says that the survivorship population encompasses more than early stage patients but survivors of long term metastatic disease as well.
Many of the challenges that Dr Denlinger says comes along with cancer survivorship is helping the patient come to terms with the new lifestyle changes that treatment and therapy causes. She adds that patients in different stages of survivorship require different care methods.
“Survivorship care has to be broad enough and as providers, we have to be willing to provide care across those three components of care but with different focuses depending on what stage of disease or what component of survivorship an individual person is living in,”Dr Denlinger says.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
